Beijing Wantai Biological Pharmacy Enterprise (603392.SH): Recombinant respiratory syncytial virus vaccine (CHO cells) approved for clinical trials.
WanTai Biopharma(603392.SH) announced that recently, its wholly-owned subsidiary WanTai Canghai received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration for the recombinant respiratory syncytial virus vaccine (CHO cell).
Beijing Wantai Biological Pharmacy Enterprise (603392.SH) announced that its wholly-owned subsidiary Wantai Canghai has received the "Drug Clinical Trial Approval Notice" issued by the National Drug Administration for the recombinant Respiratory Syncytial Virus (RSV) vaccine (CHO cells).
It is reported that the recombinant RSV vaccine (CHO cells) was jointly developed by Xiamen University and Wantai Canghai, using gene engineering recombinant technology to produce recombinant protein vaccines using CHOZN cells. The main active ingredient is the self-developed RSV fusion prereceptor membrane fusion protein F. Preclinical data shows that the product is safe and can induce RSV-specific protective immune responses in animals such as mice, rats, guinea pigs, and crab-eating macaques.
Related Articles
XD INC (02400) spent HKD 7.8391 million on March 16 to repurchase 110,000 shares.
DT Capital (00356) announces a joyful profit forecast, with an expected annual net profit attributable to shareholders not less than HK$2 million, turning losses into profits year-on-year.
SMART FISH(00139) issues a profit warning, expecting an annual pre-tax loss of not less than approximately 190 million Hong Kong dollars, representing an increase from the previous year.
XD INC (02400) spent HKD 7.8391 million on March 16 to repurchase 110,000 shares.
DT Capital (00356) announces a joyful profit forecast, with an expected annual net profit attributable to shareholders not less than HK$2 million, turning losses into profits year-on-year.
SMART FISH(00139) issues a profit warning, expecting an annual pre-tax loss of not less than approximately 190 million Hong Kong dollars, representing an increase from the previous year.
